BCAB News & Events

BioAtla's Board of Directors has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including the sale of preclinical and clinical assets, licensing transactions, strategic partnerships or other corporate transactions. Concurrently, the Company is implementing a restructuring plan to significantly reduce operating expenses, including a workforce reduction of approximately 70% and expansion of cost-containment measures. The Company intends to retain all employees essential for supporting value creation as part of its strategic review. BioAtla has engaged Tungsten Advisors as the Company's exclusive strategic financial advisor. There can be no assurance that this process will result in any such transaction. BioAtla does not intend to provide updates until the Board of Directors approves a specific action or otherwise determines whether disclosure is appropriate or required.

BioAtla files $200M mixed securities shelf

BioAtla and GATC Health announced a SPV transaction to advance ozuriftamab vedotin in a Phase 3 Study in 2L+ oropharyngeal squamous cell carcinoma/ As part of the SPV transaction, BioAtla will receive an initial $5M for general operating and 2L+ OPSCC clinical trial expenses from Inversagen AI, a newly formed company with a mission to cure age-related diseases. Inversagen AI was formed by GATC Health and Inversagen. The initial closing of the SPV transaction will occur concurrently with the initial closing of Inversagen AI'ss financing and is expected to occur by January 30, 2026, with the remaining $35M anticipated to close later in Q1 2026 when the Oz-V registrational clinical study is expected to begin, in each case subject to completion of financings by Inversagen AI and customary closing conditions. Inversagen AI will receive an aggregate 35% ownership stake in Oz-V, while BioAtla will retain 65% ownership across all Oz-V solid tumor indications after completion of the transaction. BioAtla and GATC Health also expect to collaborate with Inversagen AI for the research and development of CAB senolytic therapies with BioAtla maintaining rights to the cancer therapeutic applications of these new therapies.